Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 10/20 | 0.39 |
| ▸ | CA2 | P00918 | 10/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24722607 | 0.96 | BLM (0.49) | BLMPMP22HSD17B10KDM4EALOX15 | |
| SCHEMBL24722998 | 0.91 | BLM (0.38) | BLMPMP22HSD17B10KDM4EALOX15 | |
| SCHEMBL2349945 | 0.90 | KDM4E (0.48) | BLMPMP22KDM4EALOX15TSHR | |
| SCHEMBL29892650 | 0.90 | KDM4E (0.48) | BLMPMP22KDM4EALOX15TSHR | |
| SCHEMBL30960193 | 0.89 | KDM4E (0.47) | BLMPMP22KDM4EALOX15TSHR | |
| SCHEMBL15865623 | 0.89 | KDM4E (0.47) | BLMPMP22KDM4EALOX15TSHR | |
| SCHEMBL31679405 | 0.88 | MRGPRX4 (0.40) | BLMPMP22HSD17B10KDM4EALOX15 | |
| SCHEMBL12453251 | 0.87 | KDM4E (0.46) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL23568184 | 0.86 | KDM4E (0.50) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL24627236 | 0.85 | MRGPRX4 (0.41) | BLMPMP22HSD17B10KDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344675-B2 | Polypeptide comprising a single-domain antibody variable region that binds delta-like ligand 3 (DLL3) and method of use thereof to make a radionuclide complex | Abdera Therapeutics Inc. (US) | 2025-07-01 | — | — | US | claimed |
| US-20250051476-A1 | DLL3 BINDING MOLECULES AND USES THEREOF | Abdera Therapeutics Inc. | 2025-02-13 | — | — | US | claimed |
| US-20260077071-A1 | Targeted Delivery of Theranostic Agents | PETER MACCALLUM CANCER INST (AU) | 2026-03-19 | — | — | US | disclosed |
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| EP-4577526-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4577578-A1 | DLL3 BINDING MOLECULES AND USES THEREOF | Abdera Therapeutics Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-12344675-B2 | Polypeptide comprising a single-domain antibody variable region that binds delta-like ligand 3 (DLL3) and method of use thereof to make a radionuclide complex | Abdera Therapeutics Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250051476-A1 | DLL3 BINDING MOLECULES AND USES THEREOF | Abdera Therapeutics Inc. | 2025-02-13 | — | — | US | disclosed |
| EP-4493578-A1 | TARGETED DELIVERY OF THERANOSTIC AGENTS | Peter MacCallum Cancer Institute (AU) | 2025-01-22 | — | — | EP | disclosed |
| US-20240207462-A1 | IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | Abdera Therapeutics Inc. (CA) | 2024-06-27 | — | — | US | disclosed |
| WO-2024044552-A1 | VHH ANTIBODY DOTA CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044551-A1 | MULTIVALENT IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044549-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044550-A1 | DLL3 BINDING MOLECULES AND USES THEREOF | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-4294845-A1 | IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | Abdera Therapeutics Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023173174-A1 | TARGETED DELIVERY OF THERANOSTIC AGENTS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2023-09-21 | — | — | WO | disclosed |
| WO-2022175750-A1 | IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | Abdera Therapeutics Inc. (CA) | 2022-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051476-A1 | DLL3 BINDING MOLECULES AND USES THEREOF | DLK1, DBNL, DVL3 | BLM 4451/4885PMP22 3449/4885HSD17B10 2790/4885 |
| US-12344675-B2 | Polypeptide comprising a single-domain antibody variable region that binds delta-like ligand 3 (DLL3) and method of use thereof to make a radionuclide complex | DLK1, CD2BP2, IGLV6-57 | BLM 4169/4885PMP22 3399/4885HSD17B10 3405/4885 |
| US-20260077071-A1 | Targeted Delivery of Theranostic Agents | CCKAR, NPY1R, NPY2R | BLM 1316/4885PMP22 3204/4885HSD17B10 2752/4885 |
| US-20240207462-A1 | IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | FCGR2A, FCGR3B, CD74 | BLM 3862/4885PMP22 3408/4885HSD17B10 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.